The North America Point of Care Molecular Diagnostics Market is projected to reach a revenue of 4,100 Million USD in 2025, up from 2,100 Million USD in 2020. The market is forecast to grow steadily, culminating at approximately 9,300 Million USD by 2035, reflecting a CAGR of about 8.2% during the forecast period. This robust trajectory is powered by rapid adoption of innovative POCT technologies across healthcare settings, ongoing investments in R&D, and the continuous need for decentralized diagnostic solutions to manage public health threats.

Read More - https://bussinessinsights.com/research-report/north-america-point-of-care-molecular-diagnostics-market

In 2025, Infectious Diseases continue to drive the majority share in Point of Care Molecular Diagnostics applications, accounting for 46% of the segment due to the persistent threat of viral outbreaks and increasing attention to antimicrobial resistance. Oncology represents 17%, buoyed by innovations in rapid tumor marker detection, while Prenatal Testing holds a noteworthy 13% market share. The ease and speed of point-of-care solutions make them increasingly relevant for Hematology and Endocrinology, though these remain secondary to the leading segments. The diverse clinical utility of POCT amplifies its role in delivering timely and accurate diagnostic information across multiple care settings.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-point-of-care-molecular-diagnostics-market

Frequently Asked Questions

Who are the key players in North America Point of Care Molecular Diagnostics Market industry?
The top five players in the North America Point of Care Molecular Diagnostics Market are Abbott Laboratories, Roche Diagnostics, Cepheid (Danaher Corporation), BioMérieux SA, and Hologic Inc. These companies lead the market due to their innovative diagnostic platforms, strong product portfolios, and expanding distribution networks across the region.

What is the North America Point of Care Molecular Diagnostics Market growth?
The North America Point of Care Molecular Diagnostics Market is experiencing robust growth, propelled by rising demand for rapid infectious disease testing. Abbott Laboratories reported a surge in molecular testing revenues due to accelerated adoption during the COVID-19 pandemic, underscoring a sustained positive outlook for the sector.

Which segment accounted for the largest North America Point of Care Molecular Diagnostics Market share?
The infectious diseases segment holds the largest share in the North America Point of Care Molecular Diagnostics Market. This dominance is attributed to the high prevalence of diseases like influenza, RSV, and HIV, and the growing preference for rapid, accurate tests in clinical and outpatient settings.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America breast biopsy devices market revenue demonstrates a steady upward trend from 2020 (USD 597 million) to an estimated USD 1,250 million by 2035. Revenue growth is propelled by high disease prevalence, ongoing technology upgrades, and expanded insurance coverage for screening and diagnostic procedures. The CAGR over this period remains robust as hospitals, diagnostic centers, and ambulatory clinics continue integrating advanced biopsy systems, contributing to substantial market expansion.

Read More - https://bussinessinsights.com/research-report/north-america-breast-biopsy-devices-market

Early Cancer Detection accounts for the highest application segment in the breast biopsy devices market in North America for 2025. Tumor Identification and Routine Screening collectively drive more than half of total procedure volumes as population-wide screening programs expand. Genetics Study and Research Applications are on an upward trajectory with the advancement of personalized medicine and genomic research. The market’s focus remains solidly on improving clinical outcomes through early intervention.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-breast-biopsy-devices-market

Frequently Asked Questions

Who are the key players in North America Breast Biopsy Devices Market industry?
The key players in the North America Breast Biopsy Devices Market include Hologic, Inc., Becton Dickinson and Company (BD), Devicor Medical Products (a division of Leica Biosystems), Argon Medical Devices, and Stryker Corporation. These companies are renowned for their broad product portfolios, technological innovations, and strategic market presence.

What is the North America Breast Biopsy Devices Market growth?
The North America Breast Biopsy Devices Market is experiencing steady growth, driven by increased breast cancer screening initiatives and advanced product launches. For example, in 2023, Hologic, Inc. introduced next-generation biopsy systems, enhancing market adoption and contributing to projected annual growth rates above 7%.

Which segment accounted for the largest North America Breast Biopsy Devices Market share?
The diagnostic segment holds the largest market share in the North America Breast Biopsy Devices Market. The rising prevalence of breast cancer, coupled with significant utilization of minimally invasive diagnostic procedures, has resulted in strong demand for breast biopsy devices across hospitals and diagnostic centers.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America Cell Expansion Market is witnessing a steady increase in revenue, rising from USD 1,420 Million in 2020 to an expected USD 2,350 Million in 2025. Strong investments, technological advancements, and expanding applications in immunotherapy and regenerative medicine are the primary growth factors. Continued demand from clinical research organizations, biotechnology firms, and academic institutes is expected to propel market revenues further, surpassing USD 4,900 Million by 2035. This trajectory demonstrates sustained growth supported by a favorable policy environment, improved infrastructure, and a mature healthcare ecosystem.

Read More - https://bussinessinsights.com/research-report/north-america-cell-expansion-market

Regenerative Medicine & Stem Cell Research ranks as the leading application segment in 2025, highlighting the region’s dynamic research and clinical translation activities. Cancer & Cell-based Research is another key area, fueled by increased funding for oncology and the success of CAR-T therapy products. Clinical Diagnostics is gaining traction due to advances in personalized medicine and cell-based assays. Tissue Engineering, Drug Screening & Development, and other applications reflect a diversified market that leverages expanded cell lines to support life sciences innovation and next-generation therapies.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-cell-expansion-market

Frequently Asked Questions

Who are the key players in North America Cell Expansion Market industry?
The top 5 players in the North America Cell Expansion Market include Thermo Fisher Scientific, Merck KGaA, Lonza Group, Becton Dickinson and Company, and Corning Incorporated. These companies offer advanced cell expansion solutions and technologies, driving innovation and supporting applications in research, regenerative medicine, and biopharmaceutical production.

What is the North America Cell Expansion Market growth?
The North America Cell Expansion Market is experiencing robust growth, propelled by increased funding in cell-based research and technological advancements. In 2023, Thermo Fisher Scientific expanded its cell therapy services to address rising demand for regenerative medicine, reflecting a strong growth trajectory in the region.

Which segment accounted for the largest North America Cell Expansion Market share?
The regenerative medicine and stem cell research segment holds the largest market share in the North America Cell Expansion Market. This dominance is attributed to the rising adoption of cell therapies and increased focus on research and clinical applications for chronic diseases and cancer treatment.

Thanks & Regards,
Priya
sales@bussinessinsights.com

From 2020 to 2035, the North America Continuous Manufacturing Market is forecast to expand consistently, reflecting escalating interest in automation and efficiency across industries. In 2025, market revenue is projected at 4,800 Million USD, up from 2,900 Million USD in 2020, and is on track to surpass 11,200 Million USD by 2035. The jump in annual revenue correlates with investments in integrated manufacturing systems, advanced analytics, and regulatory support for digital transformation. Sustained growth is anticipated as new segments and applications emerge, broadening the region’s adoption of these technologies.

Read More - https://bussinessinsights.com/research-report/north-america-continuous-manufacturing-market

The pharmaceutical industry commands the majority of the continuous manufacturing market share in North America, benefiting from regulatory encouragement and a focus on consistent product quality. The chemical and food & beverage segments are robust, with process efficiency and higher throughput driving continuous adoption. Petrochemical and cosmetics applications are climbing, although to a lesser extent, while the 'Others' segment captures emerging uses such as specialty materials and nutraceuticals. This distribution underscores the sector’s established alignment with demanding, quality-centric industries that value scalability and flexibility.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-continuous-manufacturing-market

Frequently Asked Questions

Who are the key players in North America Continuous Manufacturing Market industry?
Key players include Thermo Fisher Scientific, GEA Group, Siemens AG, Bosch Packaging Technology, and Pfizer Inc. These organizations are renowned for advancing process automation, enhancing pharmaceutical production efficiency, and investing in R&D to provide innovative continuous manufacturing solutions throughout the North American pharmaceutical sector.

What is the North America Continuous Manufacturing Market growth?
The North America Continuous Manufacturing Market has witnessed robust growth, registering a CAGR of over 10% in recent years. Key drivers include Pfizer's investments in advanced manufacturing technologies, particularly for continuous production of oral solid dosage forms, to streamline and accelerate pharmaceutical manufacturing processes.

Which segment accounted for the largest North America Continuous Manufacturing Market share?
The pharmaceutical application segment holds the largest market share in North America Continuous Manufacturing Market. Increasing demand for efficient production of oral solid dosage forms, as well as regulatory support from the US FDA, have supported adoption among leading pharmaceutical companies for high-volume drug production.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America disposable medical device sensors market is projected to experience robust growth between 2020 and 2035. In 2025, the market is estimated at 4,800 Million, with strong development expected to push the value to 12,500 Million by 2035. This upward trend is driven by heightened adoption of patient monitoring and diagnostic applications, ongoing innovation among key manufacturers, and expanding distribution through online and retail channels. The year-on-year growth signals resilient demand despite regulatory and cost-related challenges, positioning North America at the forefront of disposable sensor innovation and market scalability.

Read More - https://bussinessinsights.com/research-report/north-america-disposable-medical-device-sensors-market

Patient monitoring will account for the largest share of disposable medical device sensors applications in North America for 2025, reflecting the pressing need for real-time, remote monitoring in both acute and chronic care settings. Diagnostics will follow, as rapid, point-of-care diagnostic tests and sensors become standard across clinics and home care scenarios. Therapeutic applications are gaining momentum, especially in minimally invasive and targeted treatments powered by disposable sensors. This distribution highlights healthcare providers’ strategic focus on early detection, preventive care, and improved patient management outcomes, amplifying demand across both hospitals and ambulatory service channels.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-disposable-medical-device-sensors-market

Thanks & Regards,
Priya
sales@bussinessinsights.com

The market has experienced a steady and significant rise in revenue, with growth sustained by technological advancements, expanded healthcare access, and increasing adoption of digital and minimally invasive medical devices. In 2025, the market is projected at USD 34,900 Million, with continuous compound annual growth rate (CAGR) propelling it beyond USD 62,300 Million by 2035. This consistent upward trajectory reflects robust demand across both established and emerging medical segments, with revenue gains attributed to a mix of innovation, M&A activity among leading players, and changing patient care paradigms.

Read More - https://bussinessinsights.com/research-report/north-america-european-medical-devices-market

The market application landscape in 2025 highlights cardiology as the leading segment due to the growing incidence of cardiovascular diseases and high demand for related diagnostic and intervention devices. Orthopedics follows, spurred by aging demographics and a surge in musculoskeletal procedures. Oncology, bolstered by advances in early diagnosis and personalized therapies, is rapidly expanding its share. Neurology, ophthalmology, and others—while smaller—are vital for specialized device development and innovation. The shifting disease burden and robust investments in therapeutic solutions ensure a dynamic and competitive application environment.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-european-medical-devices-market

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America NGS-based RNA-sequencing market is expected to exhibit steady revenue growth from 2020 through 2035, underpinned by rapid technology adoption, expanding clinical applications, and increasing R&D spending. In 2025, total market revenue is projected to reach approximately 1,350 Million USD, with a sustained annual growth rate driven by advancements in sequencing technologies, integration of automation, and higher throughput capabilities. The market is forecast to surpass 3,540 Million USD by 2035 as genetic and transcriptomic profiling become routine in both academic and clinical environments.

Read More - https://bussinessinsights.com/research-report/north-america-ngs-based-rna-sequencing-market

Diagnostics is poised to be the leading application for NGS-based RNA-sequencing in North America by 2025, as hospitals and clinical labs increasingly incorporate transcriptomic data into oncology and rare disease diagnosis. Closely behind, drug discovery is leveraging RNA-seq for target identification and safety assessments, while biomarker discovery continues to gain momentum with a surge in translational research programs. This broadening adoption across healthcare and pharmaceutical research is expected to drive continued growth and innovation throughout the forecast period.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-ngs-based-rna-sequencing-market

Frequently Asked Questions

Who are the key players in North America NGS-based RNA-sequencing Market industry?
The top 5 players are Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and PerkinElmer. These companies drive innovation through advanced sequencing platforms, sample preparation solutions, and comprehensive bioinformatics. Their extensive product portfolios, strong distribution networks, and continuous investments in R&D significantly influence the North American RNA-sequencing landscape.

What is the North America NGS-based RNA-sequencing Market growth?
The North America NGS-based RNA-sequencing market has experienced robust growth, primarily driven by rising R&D activities and adoption in clinical diagnostics. For example, Illumina reported double-digit revenue growth in 2023, fueled by expanding applications in transcriptomics, personalized medicine, and biomarker discovery among research and healthcare institutions.

Which segment accounted for the largest North America NGS-based RNA-sequencing Market share?
In 2023, the research and academic institutes segment held the largest market share, owing to increased government funding and large-scale genomic studies. These organizations utilize NGS-based RNA sequencing for basic research, disease characterization, and biomarker discovery, driving significant adoption across projects and collaborations.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The market is expected to grow from $102,500 million in 2021 to $165,000 million in 2035, reflecting sustained expansion in technological adoption, chronic disease management, and supportive regulatory reforms. Annual revenue increases are particularly noticeable from 2025 onwards, as digital health and remote patient monitoring solutions consolidate their foothold in the market, aided by continued venture capital and public funding. Major players are anticipated to deepen their market penetration via mergers and acquisitions throughout this period. The trajectory demonstrates the North American region's leadership in medical device innovation and commercialization.

Read More - https://bussinessinsights.com/research-report/north-america-medical-device-technologies-market

In 2025, diagnostics lead the North America Medical Device Technologies Market with a 35% share, reflecting the continuing necessity for advanced diagnostic tools in early disease detection and personalized medicine. Therapeutics emerges second at 28%, as the shift toward minimally invasive procedures and advanced implantable devices gains traction. Monitoring devices capture 16%, with patient demand for continuous health tracking on the rise. Surgery and research applications occupy 12% and 9% of the market respectively. This segmentation illustrates growing investment across the entire care continuum, from diagnosis to treatment and post-care monitoring.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-medical-device-technologies-market

Frequently Asked Questions

Who are the key players in North America Medical Device Technologies Market industry?
The top five players are Medtronic, Johnson & Johnson, GE Healthcare, Abbott Laboratories, and Stryker Corporation. These companies lead through advanced product development, extensive R&D investments, and broad portfolios in cardiology, diagnostics, surgery, and digital health technologies, securing strong market presence across North America.

What is the North America Medical Device Technologies Market growth?
The North America Medical Device Technologies Market is experiencing steady growth, driven by technological advancements and increasing chronic disease prevalence. For example, Abbott Laboratories reported significant revenue increases in its diagnostics segment, fueled by innovations in point-of-care testing and continuous glucose monitoring in 2023.

Which segment accounted for the largest North America Medical Device Technologies Market share?
The diagnostic imaging segment holds the largest market share, owing to the rising adoption of MRI, CT, and ultrasound systems in hospitals and clinics. Increasing investment in imaging solutions for early disease detection is fueling strong demand, especially from top healthcare providers using GE Healthcare and Siemens equipment.

Thanks & Regards,
Priya
sales@bussinessinsights.com

Over the 2020-2035 period, North America's chiral chromatography column market is forecast to expand steadily, reaching a projected USD 740 million by 2035. Increasing investments in research and quality control, especially in pharmaceuticals, biopharma, and environmental sectors, fuel this growth. The integration of newer column chemistries and advanced chromatographic techniques continuously drives replacement and upgrade cycles, resulting in a positive revenue trajectory year-on-year. Market players are focused on innovation, customization, and service support to sustain revenue growth.

Read More - https://bussinessinsights.com/research-report/north-america-chiral-chromatography-column-market

Pharmaceutical and biotechnology industries dominate the application landscape for chiral chromatography columns in North America, accounting for the largest market share in 2025. This is primarily driven by the need for enantiomeric separation and purity testing in drug development and production. Food & beverage testing has seen remarkable growth amid rising regulatory standards, closely followed by environmental, chemical, and cosmetics sectors. The versatility and adaptability of modern chiral columns in addressing diverse separation requirements are expanding their use beyond traditional pharmaceutical laboratories.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-chiral-chromatography-column-market

Frequently Asked Questions

Who are the key players in North America Chiral Chromatography Column Market industry?
The top five players are Agilent Technologies, Waters Corporation, Thermo Fisher Scientific, Shimadzu Corporation, and Merck KGaA. These companies lead through advanced R&D, robust product portfolios, and strong distribution networks, providing highly efficient chiral column solutions for pharmaceutical, food, and chemical applications across North America.

What is the North America Chiral Chromatography Column Market growth?
The North America Chiral Chromatography Column Market has experienced notable growth in 2023, driven by increased pharmaceutical research and rising demand for enantiomeric purity. Companies like Agilent Technologies have seen significant market expansion due to innovative product launches and enhanced application in drug development.

Which segment accounted for the largest North America Chiral Chromatography Column Market share?
The pharmaceutical and biotechnology applications segment registered the largest market share, driven by the increasing need for enantiomeric separation in drug development and quality control. Rising regulatory demands for chiral purity in pharmaceuticals have further fueled adoption of chiral chromatography columns in North America.

Thanks & Regards,
Priya
sales@bussinessinsights.com

The North America Remote Patient Monitoring market is experiencing robust revenue growth, moving from $1,600 Million in 2020 to an estimated $7,800 Million by 2035. Early pandemic-driven adoption established a new baseline for remote healthcare delivery. Continued technological advancements, coupled with expanding reimbursement frameworks and a rising elderly population, are expected to maintain momentum. The market’s upward trajectory is also fueled by a sharp rise in chronic disease prevalence and ongoing investment by leading vendors into AI, cloud, and IoT integration. Annual revenue increments reflect double-digit compound annual growth rates across the forecast period.

Read More - https://bussinessinsights.com/research-report/north-america-remote-patient-monitoring-(rpm)-market

Cardiac monitoring dominates RPM applications in 2025, supported by high prevalence of cardiovascular conditions and advanced remote ECG and heart rhythm tracking. Diabetes management is the second largest segment, fueled by adoption of continuous glucose monitoring systems. Multi-parameter monitoring, respiratory, and blood pressure applications represent strong growth areas. The spread of RPM use across these segments highlights the versatility of remote care solutions, their impact on chronic disease management, and the growing acceptance among healthcare providers and patients for remote health monitoring as standard practice.

Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-remote-patient-monitoring-(rpm)-market

Thanks & Regards,
Priya
sales@bussinessinsights.com